Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_assertion type Assertion NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_head.
- NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_assertion description "[The validation of KRAS mutations as a negative marker of response to anti-epidermal growth factor receptor (EGFR) antibodies has meant a seminal advance towards treatment individualisation of colorectal cancer (CRC) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_provenance.
- NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_assertion evidence source_evidence_literature NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_provenance.
- NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_assertion SIO_000772 20234366 NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_provenance.
- NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_assertion wasDerivedFrom befree-2016 NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_provenance.
- NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_assertion wasGeneratedBy ECO_0000203 NP800410.RAXI6GU23cwOfsdrC288UjVUCCK71d_7Xgl9j_mtn34uo130_provenance.